For instance, while pembrolizumab and atezolizumab are effective PD-1/PDL-1 inhibitors in second-line advanced non-small cell lung cancer (NSCLC), avelumab and durvalumab were effective in late-phase clinical testing (239). This evidence concerns the gene CD274 and non-small cell lung carcinoma.